Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
NCT00318721 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20000
Last updated 2009-11-04
Summary
A cluster-randomized vector control trial in Bihar, India, and neighboring Nepal, will test the efficacy of long-lasting impregnated bednets (LLINs, Permanets) for reducing visceral leishmaniasis incidence. The intervention unit is the village (400-1000 people). The study is designed to detect a 50% reduction in Leishmania donovani incidence in intervention compared to control clusters over 2 years. 24 clusters (selected as high incidence during previous years) will be randomly allocated to intervention or control. Following health education, and with informed consent, all households in intervention villages will receive free Permanets (from September 2006). Net usage will be monitored and new nets provided if required. Control villages will not be given untreated nets, as - although commonly used in this region - their effectiveness against sandflies has not been proven. Pre-intervention infection status of villagers (\>2 yrs) will be evaluated serologically from finger-prick blood (and past/current disease status noted). Incident infections will be recorded by 3-monthly active search for clinical cases, and by annual serological diagnoses to detect subclinical infections. All villagers (\>2yrs) will be leishmanin skin tested at the end of the trial for further subclinical infection detection, and sera from a sub-sample will be tested for antibodies to sandfly saliva antigens (a measure of sandfly exposure). All clinical cases will be given free treatment. Free Permanets will be provided to control villages after the trial. Complementary studies involve entomological surveillance by light traps in a sample of houses and social/economic questionnaire surveys. The entomological surveys will test whether community-wide use of LLINs provides any mass effect, which could protect those in the community who fail to use LLIN for any reason.
Conditions
- Visceral Leishmaniasis
- Kala Azar
Interventions
- DEVICE
-
Long Lasting Impregnated Nets (LLIN)
Distribution of LLIN in selected clusters
Sponsors & Collaborators
-
Institute of Tropical Medicine, Belgium
collaborator OTHER -
University Hospital, Geneva
collaborator OTHER -
Rajendra Memorial Research Institute of Medical Sciences
collaborator OTHER -
Institute of Medical Sciences of the Banaras Hindu University, India
collaborator OTHER -
International Centre for Diarrhoeal Disease Research, Bangladesh
collaborator OTHER -
B.P. Koirala Institute of Health Sciences
collaborator OTHER -
London School of Hygiene and Tropical Medicine
lead OTHER
Principal Investigators
-
Marleen Boelaert, Dr · Prince Leopold Institute of Tropical Medicine in Antwerp (ITM), Belgium
-
Clive Davies, Dr. · London School of Hygiene and Tropical Medicine
-
Jean Claude Dujardin, Dr · Prince Leopold Institute of Tropical Medicine in Antwerp (ITM), Belgium
-
Suman Rijal, Dr. · B.P. Koirala Institute of Heath Sciences, Nepal
-
Shyam Sundar, Dr · Institute of Medical Sciences of the Banaras Hindu University, India
-
Francois Chappuis, Dr. · University Hospital, Geneva
-
Beena Varghese, Dr · Centre for Health and Population Research (ICDDR,B), Dhaka, Bangladesh
-
Marc Coosemans, Dr · Prince Leopold Institute of Tropical Medicine in Antwerp (ITM), Belgium.
-
Veerle Vanlerberghe, Dr. · Prince Leopold Institute of Tropical Medicine in Antwerp (ITM), Belgium.
-
Diwarkar Dinesh, Dr · Rajendra Memorial Research Institute of Medical Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-06-30
- Primary Completion
- 2008-12-31
- Completion
- 2009-11-30
Countries
- India
- Nepal
Study Locations
More Related Trials
-
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
NCT03303898 ·Status: COMPLETED ·Phase: NA
-
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
NCT00317629 ·Status: TERMINATED ·Phase: PHASE3
-
Combination Chemotherapy for the Treatment of Indian Kala-Azar
NCT00370825 ·Status: COMPLETED ·Phase: PHASE2
-
Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin
NCT00429715 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
NCT05449717 ·Status: COMPLETED
-
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
NCT04311671 ·Status: COMPLETED ·Phase: PHASE3
-
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
NCT01032187 ·Status: COMPLETED ·Phase: PHASE4
-
Diagnosis and Treatment of Leishmania Infections
NCT00344188 ·Status: RECRUITING
-
Improved Case Detection and Vector Control for Visceral Leishmaniasis
NCT03269006 ·Status: COMPLETED ·Phase: NA
-
Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)
NCT00429780 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Repeat Ivermectin Mass Drug Administrations for MALaria Control II
NCT03967054 ·Status: COMPLETED ·Phase: PHASE3
-
Spatial Repellents for Vector Control
NCT04795648 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru
NCT03762070 ·Status: UNKNOWN
-
A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar
NCT00497601 ·Status: COMPLETED ·Phase: PHASE2
-
The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
NCT02533336 ·Status: TERMINATED ·Phase: PHASE3
-
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants
NCT06558643 ·Status: COMPLETED ·Phase: PHASE1
-
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
NCT06179732 ·Status: COMPLETED ·Phase: PHASE3
-
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
NCT03784248 ·Status: ACTIVE_NOT_RECRUITING
-
Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria
NCT06917040 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
NCT00111514 ·Status: COMPLETED ·Phase: PHASE1
-
Miltefosine for Mucosal Leishmaniasis
NCT00373776 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar
NCT00371995 ·Status: COMPLETED ·Phase: PHASE2
-
Amphotericin B Treatment in Visceral Leishmaniasis
NCT00310505 ·Status: COMPLETED ·Phase: NA
-
Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
NCT06118749 ·Status: TERMINATED
-
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
NCT00216346 ·Status: COMPLETED ·Phase: PHASE3